Sharps Compliance Reports Fiscal 2019 Fourth Quarter Results
- Fourth quarter 2019 revenue of
$12.2 million , an increase of 23% over prior year - Record fourth quarter customer billings of
$12.7 million , an increase of 31% over prior year - Gross margin improved to 32%
- Net income of
$0.5 million and earnings per share of$0.03 for the quarter - Retail market billings increased 54%
- Unused medications business grew 41%
- Pharmaceutical Manufacturer billings improved by more than 180%
- Route-based business increased 27%
Revenue in the fourth quarter of fiscal 2019 was
“As we kick-off fiscal 2020, we believe our diverse capabilities position us well to continue to grow our market share in the small to medium waste generator segment which encompasses the key customers for our portfolio of solutions. We are unique in our strategy to structure our service offering to include route-based pick-up, mailback, or a combination of both, to meet the needs of our customers in an effective and cost-efficient service model.
“As the leader in the patient dispensed unused medication management business, we continue to see strong demand for our unused medications solutions, including the MedSafe and TakeAway Medication Recovery System Envelopes. This part of our business increased 41% over the fourth quarter last year, 32% over the sequential quarter and accounts for 18% of our overall billings in the fourth quarter of 2019. As of
Fourth Quarter Review
Professional market billings increased 13% to
Fourth quarter Retail market billings grew 54% from
Pharmaceutical Manufacturer billings increased 187% to
Government billings increased 29% to
Additional Operating Results
The Company reported gross margin of 32% for the fourth quarter of fiscal 2019, an increase compared to gross margin of 30% in the same prior year quarter. SG&A increased approximately 10.5% to
Sharps recorded EBITDA of
Full Year 2019 Results
Sharps recorded revenue of
Gross margin increased to 30% for fiscal 2019 as compared to 28.0% in fiscal 2018. SG&A expense increased 8% to
The Company achieved net income of
Sharps more than doubled EBITDA in fiscal 2019 to
Financial Flexibility and a Strong Balance Sheet
Cash was
Looking Forward
Mr. Tusa concluded, “Looking forward to fiscal 2020, we see the
Fourth Quarter Fiscal Year 2019 Webcast and Conference Call
The Company will host a teleconference today beginning at
The Sharps conference call can be accessed by domestic callers by dialing (877) 407-0782. International callers may access the call by dialing (201) 689-8567. The webcast can be monitored at www.sharpsinc.com.
A telephonic replay will be available through
About
Headquartered in
More information on the Company and its products can be found on its website at: www.sharpsinc.com.
Safe Harbor Statement
The information made available in this news release contains certain forward-looking statements which reflect
Non-GAAP Measures
This release contains certain financial information not derived in accordance with generally accepted accounting principles (“GAAP”), including customer billings information and EBITDA. The Company believes this information is useful to investors and other interested parties. EBITDA is a significant performance metric used by management and by external users of our financial statements such as investors, research analysts and others to assess the financial performance of our assets without regard to financing methods, capital structure or historical cost basis; the ability of our assets to generate cash sufficient to pay interest costs and support our indebtedness; and our operating performance and return on capital as compared to those of other companies in our industry. Such information should not be considered as a substitute for any measure derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included as an attachment to this release.
For more information contact: | |||
Diana P. Diaz Sharps Compliance Corp. Vice President and Chief Financial Officer Phone: (713) 660-3547 Email: ddiaz@sharpsinc.com |
John Nesbett/Jennifer Belodeau IMS Investor Relations Phone: (203) 972-9200 Email: jnesbett@institutionalms.com |
||
FINANCIAL TABLES FOLLOW
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
Three-Months Ended | Year Ended | ||||||||||||||||||
June 30, | June 30, | ||||||||||||||||||
2019 | 2018 | % Change | 2019 | 2018 | % Change | ||||||||||||||
Revenue | $ | 12,174 | $ | 9,912 | 22.8 | % | $ | 44,312 | $ | 40,141 | 10.4 | % | |||||||
Cost of revenue | 8,282 | 6,965 | 18.9 | % | 31,042 | 28,739 | 8.0 | % | |||||||||||
Gross profit | 3,892 | 2,947 | 32.1 | % | 13,270 | 11,402 | 16.4 | % | |||||||||||
Gross margin | 32.0 | % | 29.7 | % | 29.9 | % | 28.4 | % | |||||||||||
SG&A expense | 3,117 | 2,822 | 10.5 | % | 12,003 | 11,168 | 7.5 | % | |||||||||||
Depreciation and amortization | 207 | 203 | 820 | 811 | |||||||||||||||
Operating Income (Loss) | 568 | (78 | ) | 447 | (577 | ) | |||||||||||||
Operating margin | 4.7 | % | (0.8 | )% | 1.0 | % | (1.4 | )% | |||||||||||
Interest income | 6 | 5 | 24 | 20 | |||||||||||||||
Interest expense | (19 | ) | (24 | ) | (87 | ) | (94 | ) | |||||||||||
Total other expense | (13 | ) | (19 | ) | (63 | ) | (74 | ) | |||||||||||
Income (loss) before income tax expense | 555 | (97 | ) | 384 | (651 | ) | |||||||||||||
Income tax expense | 65 | 49 | 170 | 21 | |||||||||||||||
Net Income (Loss) | $ | 490 | $ | (146 | ) | $ | 214 | $ | (672 | ) | |||||||||
Net Income (Loss) Per Share | |||||||||||||||||||
Basic and diluted | $ | 0.03 | $ | (0.01 | ) | $ | 0.01 | $ | (0.04 | ) | |||||||||
Weighted Average Shares Outstanding | |||||||||||||||||||
Basic | 16,141 | 16,082 | 16,116 | 16,055 | |||||||||||||||
Diluted | 16,150 | 16,082 | 16,123 | 16,055 | |||||||||||||||
Condensed Consolidated Balance Sheets
(in thousands)
(Unaudited)
June 30, | June 30, | ||||||
2019 | 2018 | ||||||
ASSETS: | |||||||
Current assets: | |||||||
Cash | $ | 4,512 | $ | 5,155 | |||
Accounts receivable, net | 9,289 | 6,370 | |||||
Inventory | 3,770 | 3,986 | |||||
Contract asset | 260 | — | |||||
Prepaid and other current assets | 922 | 739 | |||||
Total current assets | 18,753 | 16,250 | |||||
Property, plant and equipment, net | 5,867 | 6,572 | |||||
Inventory, net of current portion | 1,046 | — | |||||
Other assets | 443 | 149 | |||||
Goodwill | 6,735 | 6,735 | |||||
Intangible assets, net | 3,196 | 3,525 | |||||
Total assets | $ | 36,040 | $ | 33,231 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY: | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 2,946 | $ | 1,500 | |||
Accrued liabilities | 2,213 | 2,061 | |||||
Current maturities of long-term debt | 517 | 537 | |||||
Contract liability | 2,502 | 1,894 | |||||
Total current liabilities | 8,178 | 5,992 | |||||
Contract liability, net of current portion | 503 | 470 | |||||
Other liabilities | 42 | 130 | |||||
Deferred tax liability | 243 | — | |||||
Long-term debt, net of current portion | 948 | 1,465 | |||||
Total liabilities | 9,914 | 8,057 | |||||
Stockholders’ equity | 26,126 | 25,174 | |||||
Total liabilities and stockholders' equity | $ | 36,040 | $ | 33,231 | |||
Supplemental Customer Billing and Revenue Information
(in thousands)
(Unaudited)
Three-Months Ended June 30, | |||||||||||||||||||||
2019 | % Total | 2018 | $ Change | % | |||||||||||||||||
BILLINGS BY MARKET: | |||||||||||||||||||||
Professional | $ | 3,912 | 30.8 | % | $ | 3,476 | $ | 436 | 12.5 | % | |||||||||||
Retail | 3,479 | 27.4 | % | 2,264 | 1,215 | 53.7 | % | ||||||||||||||
Home Health Care | 2,072 | 16.3 | % | 2,002 | 70 | 3.5 | % | ||||||||||||||
Pharmaceutical Manufacturer | 1,462 | 11.5 | % | 510 | 952 | 186.7 | % | ||||||||||||||
Assisted Living | 645 | 5.1 | % | 633 | 12 | 1.9 | % | ||||||||||||||
Government | 760 | 6.0 | % | 590 | 170 | 28.8 | % | ||||||||||||||
Environmental | 84 | 0.7 | % | 76 | 8 | 10.5 | % | ||||||||||||||
Other | 301 | 2.2 | % | 182 | 119 | 65.4 | % | ||||||||||||||
Subtotal | $ | 12,715 | 100.0 | % | $ | 9,733 | $ | 2,982 | 30.6 | % | |||||||||||
GAAP Adjustment * | (541 | ) | 179 | (720 | ) | ||||||||||||||||
Revenue Reported | $ | 12,174 | $ | 9,912 | $ | 2,262 | 22.8 | % | |||||||||||||
Year Ended June 30, | |||||||||||||||||||||
2019 | % Total | 2018 | $ Change | % | |||||||||||||||||
BILLINGS BY MARKET: | |||||||||||||||||||||
Professional | $ | 15,071 | 33.5 | % | $ | 13,110 | $ | 1,961 | 15.0 | % | |||||||||||
Retail | 11,481 | 25.5 | % | 7,885 | 3,596 | 45.6 | % | ||||||||||||||
Home Health Care | 7,800 | 17.3 | % | 7,989 | (189 | ) | (2.4 | )% | |||||||||||||
Pharmaceutical Manufacturer | 4,146 | 9.2 | % | 4,482 | (336 | ) | (7.5 | )% | |||||||||||||
Assisted Living | 2,542 | 5.7 | % | 2,515 | 27 | 1.1 | % | ||||||||||||||
Government | 2,468 | 5.5 | % | 2,074 | 394 | 19.0 | % | ||||||||||||||
Environmental | 290 | 0.6 | % | 891 | (601 | ) | (67.5 | )% | |||||||||||||
Other | 1,175 | 2.7 | % | 818 | 357 | 43.6 | % | ||||||||||||||
Subtotal | $ | 44,973 | 100.0 | % | $ | 39,764 | $ | 5,209 | 13.1 | % | |||||||||||
GAAP Adjustment* | (661 | ) | 377 | (1,038 | ) | ||||||||||||||||
Revenue Reported | $ | 44,312 | $ | 40,141 | $ | 4,171 | 10.4 | % | |||||||||||||
*Represents the net impact of the revenue recognition adjustments to arrive at reported GAAP revenue. Customer billings include all invoiced amounts for products shipped or services rendered during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales, (ii) recognition of certain revenue associated with product returned for treatment and destruction and (iii) provisions for certain product returns and discounts to customers which are accounted for as reductions in sales in the same period the related sales are recorded. Most of the difference between customer billings and GAAP revenue is reflected in the Company’s balance sheet as Contract Liability. | |||||||||||||||||||||
Supplemental Customer Billing by Solution Information
(in thousands)
(Unaudited)
Three-Months Ended June 30, | ||||||||||||||||||
2019 | % Total | 2018* | $ Change | % | ||||||||||||||
BILLINGS BY SOLUTION: | ||||||||||||||||||
Mailbacks | $ | 6,819 | 53.6 | % | $ | 5,110 | $ | 1,709 | 33.4 | % | ||||||||
Route-Based Pickup | 2,564 | 20.2 | % | 2,013 | 551 | 27.4 | % | |||||||||||
Unused Medications | 2,242 | 17.6 | % | 1,586 | 656 | 41.4 | % | |||||||||||
Third Party Treatment | 84 | 0.7 | % | 76 | 8 | 10.5 | % | |||||||||||
Other | 1,006 | 7.9 | % | 948 | 58 | 6.1 | % | |||||||||||
Total Billings By Solution | $ | 12,715 | 100.0 | % | $ | 9,733 | $ | 2,982 | 30.6 | % | ||||||||
Year Ended June 30, | ||||||||||||||||||
2019 | % Total | 2018* | $ Change | % | ||||||||||||||
BILLINGS BY SOLUTION: | ||||||||||||||||||
Mailbacks | $ | 25,162 | 55.9 | % | $ | 21,895 | $ | 3,267 | 14.9 | % | ||||||||
Route-Based Pickup | 9,029 | 20.1 | % | 7,492 | 1,537 | 20.5 | % | |||||||||||
Unused Medications | 6,936 | 15.4 | % | 5,907 | 1,029 | 17.4 | % | |||||||||||
Third Party Treatment | 290 | 0.6 | % | 891 | (601 | ) | (67.5 | )% | ||||||||||
Other | 3,556 | 8.0 | % | 3,579 | (23 | ) | (0.6 | )% | ||||||||||
Total Billings By Solution | $ | 44,973 | 100.0 | % | $ | 39,764 | $ | 5,209 | 13.1 | % | ||||||||
*Certain prior year amounts have been reclassified to conform to current year presentation. | ||||||||||||||||||
Supplemental Customer Billing by Channel Information
(in thousands)
(Unaudited)
Three-Months Ended June 30, | ||||||||||||||||||
2019 | % Total | 2018 | $ Change | % Change | ||||||||||||||
BILLINGS BY CHANNEL: | ||||||||||||||||||
Direct Sales | $ | 6,725 | 52.9 | % | $ | 4,643 | $ | 2,082 | 44.8 | % | ||||||||
Distributors | 3,788 | 29.8 | % | 3,133 | 655 | 20.9 | % | |||||||||||
Inside and Online Sales | 2,202 | 17.3 | % | 1,957 | 245 | 12.5 | % | |||||||||||
Total Billings By Channel | $ | 12,715 | 100.0 | % | $ | 9,733 | $ | 2,982 | 30.6 | % | ||||||||
Year Ended June 30, | ||||||||||||||||||
2019 | % Total | 2018 | $ Change | % Change | ||||||||||||||
BILLINGS BY CHANNEL: | ||||||||||||||||||
Direct Sales | $ | 23,288 | 51.9 | % | $ | 20,981 | $ | 2,307 | 11.0 | % | ||||||||
Distributors | 13,225 | 29.4 | % | 11,605 | 1,620 | 14.0 | % | |||||||||||
Inside and Online Sales | 8,460 | 18.7 | % | 7,178 | 1,282 | 17.9 | % | |||||||||||
Total Billings By Channel | $ | 44,973 | 100.0 | % | $ | 39,764 | $ | 5,209 | 13.1 | % | ||||||||
Supplemental Table to Reconcile Net Income (Loss) to EBITDA*
(in thousands)
(Unaudited)
Three-Months Ended | Year Ended | ||||||||||||||
June 30, | June 30, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
Net Income (Loss) | $ | 490 | $ | (146 | ) | $ | 214 | $ | (672 | ) | |||||
Income tax expense | 65 | 49 | 170 | 21 | |||||||||||
Interest expense, net | 13 | 19 | 63 | 74 | |||||||||||
Depreciation and amortization | 430 | 387 | 1,663 | 1,561 | |||||||||||
EBITDA | $ | 998 | $ | 309 | $ | 2,110 | $ | 984 | |||||||
*The Company defines earnings before interest, taxes, depreciation and amortization (“EBITDA”) as net income (loss), plus income tax expense, net interest expense, and depreciation and amortization. Other companies may define EBITDA differently. EBITDA is presented because it is a financial measure that is frequently requested by third parties. However, EBITDA is not considered under generally accepted accounting principles as a primary measure of an entity’s financial results, and accordingly, EBITDA should not be considered an alternative to operating income (loss), net income (loss), or cash flows as determined under generally accepted accounting principles and as reported by the Company. |
Source: Sharps Compliance Corp.